SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Clinical trials for SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS explained in plain language.
Never miss a new study
Get alerted when new SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS trials appear
Sign up with your email to follow new studies for SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill could slow MS disability in major trial
Disease control Recruiting nowThis Phase 3 trial tests an oral drug called orelabrutinib against a placebo in about 990 people with non-active secondary progressive multiple sclerosis (MS). The goal is to see if the drug can delay worsening disability over 24 to 60 months. Participants are randomly assigned t…
Matched conditions: SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: Zenas BioPharma (USA), LLC • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
MS patients may soon swap IV drips for quick shots
Disease control Recruiting nowThis Phase 3 trial tests whether a simple injection of frexalimab every 4 weeks works as well as the standard IV infusion for adults with relapsing or non-active progressive multiple sclerosis. About 160 participants will be randomly assigned to one of the two methods. The study …
Matched conditions: SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: Sanofi • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Could a single infusion of modified immune cells tame autoimmune attacks?
Disease control Recruiting nowThis early study tests a new treatment called azercabtagene zapreleucel (azer-cel) for people with B-cell mediated autoimmune disorders like multiple sclerosis and neuromyelitis optica. The treatment uses a patient's own immune cells that are modified in a lab to target and destr…
Matched conditions: SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE1 • Sponsor: TG Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a cancer therapy tame multiple sclerosis? new trial launches
Disease control Recruiting nowThis early-stage trial is testing a new treatment called AZD0120 for people with multiple sclerosis (MS) that has not responded to other therapies. AZD0120 is a type of immune cell therapy (CAR-T) designed to target and reset the immune system. The study will enroll 24 adults age…
Matched conditions: SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Engineered immune cells take on multiple sclerosis and other autoimmune brain diseases
Disease control Recruiting nowThis early-phase study tests a new treatment called RD06-05, which uses specially engineered immune cells (CAR-T cells) to target and calm the immune system in people with neurological autoimmune diseases like multiple sclerosis, myasthenia gravis, chronic inflammatory demyelinat…
Matched conditions: SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: EARLY_PHASE1 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Could a stem cell transplant tame Hard-to-Control MS?
Disease control Recruiting nowThis study compares a stem cell transplant (using a person's own cells) against the best available medications for people with relapsing multiple sclerosis that hasn't responded to treatment. About 156 participants will be randomly assigned to one of the two approaches and follow…
Matched conditions: SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Nasal spray could tame brain inflammation in progressive MS
Disease control Recruiting nowThis phase 2a trial tests a nasal spray called foralumab in 54 people with non-active secondary progressive multiple sclerosis (SPMS). The spray contains an antibody that aims to calm overactive immune cells in the brain. Participants will receive either a low dose, a high dose, …
Matched conditions: SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE2 • Sponsor: Tiziana Life Sciences LTD • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Cancer drug ixazomib tested as potential MS treatment
Disease control Recruiting nowThis phase 1b trial is testing whether ixazomib, a drug already used for multiple myeloma, is safe for people with multiple sclerosis. The study will enroll 72 adults with relapsing-remitting or progressive MS. Participants will receive either ixazomib or a placebo for up to 24 m…
Matched conditions: SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE1 • Sponsor: Queen Mary University of London • Aim: Disease control
Last updated Jun 26, 2026 13:46 UTC
-
New brain scans aim to spot inflammation in MS and Alzheimer's
Knowledge-focused Recruiting nowThis study uses special PET scans to look for brain inflammation in people with multiple sclerosis (MS) and Alzheimer's disease. Researchers will compare two radioactive tracers, [F-18]PBR06 and [C-11]PBR28, to see which works better. Up to 250 participants, including healthy vol…
Matched conditions: SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE1, PHASE2 • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
New brain scan study aims to improve MS diagnosis and monitoring
Knowledge-focused Recruiting nowThis study looks at how the brain uses sugar (glucose) in people with multiple sclerosis (MS) compared to healthy volunteers. Researchers will use a special PET scan to measure brain activity and compare it with MRI scans and blood tests. The goal is to find better ways to diagno…
Matched conditions: SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: PHASE4 • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Scientists use novel PET tracer to peer into brains of progressive MS patients
Knowledge-focused Recruiting nowThis study aims to understand how brain connections (synapses) are lost in progressive multiple sclerosis (MS). Researchers will use a new type of PET scan to measure synaptic density in 30 people with progressive MS, relapsing-remitting MS, and healthy volunteers. The goal is to…
Matched conditions: SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS
Phase: EARLY_PHASE1 • Sponsor: Brigham and Women's Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:09 UTC